Forecasting the Economic Burden of Cardiovascular Disease and Stroke in the United States Through 2050

This AHA presidential advisory projects the real (inflation-adjusted) health care and societal costs of cardiovascular disease in the United States through 2050. The core finding: CVD risk factor health care costs are projected to triple from $400 billion in 2020 to $1.34 trillion in 2050; CVD condition costs nearly quadruple from $393 billion to $1.49 trillion. Total CVD burden rises from 2.7% to 4.6% of US GDP.

The methodology is substantial — nationally representative data from MEPS and the US Census, regression-based cost estimation, human capital productivity loss calculations, bootstrapped uncertainty intervals, and 2022 constant dollars throughout. Prevalence trends are drawn from 2009–2019 historical data projected forward using established demographic shifts, not optimistic assumptions.

Stroke emerges as the largest cost driver by both absolute and relative increase: $357 billion in additional costs, a 535% relative increase. Heart failure and coronary heart disease follow. Per-person annual costs are striking: stroke at $35,000, heart failure at $18,000, coronary heart disease at $13,000. Medicare faces a particularly severe trajectory, projected to increase from $384 billion to $1.2 trillion in CVD costs — a 214% increase — driving structural pressure on federal health spending.

Racial and ethnic cost growth is concentrated in Hispanic and Asian American populations — 489% and 497% increases, respectively — driven largely by projected demographic growth. These projections predate GLP-1 receptor agonists at scale, which could materially alter the obesity and diabetes cost trajectories.

The policy implications are direct: without structural interventions, the cardiovascular care system will consume an unsustainable fraction of national output. Individual-level interventions alone are insufficient; food and built environment reforms, pharmaceutical price controls, and targeted prevention programs for high-risk populations are required.

We rate the evidence moderate and the policy significance high. This AHA presidential advisory projecting US CVD economic burden through 2050 — $1.85 trillion by 2050, 4.6% of GDP — provides the most comprehensive quantitative case yet assembled for aggressive, system-level cardiovascular prevention investment.